A Board Member Bought International Game Technology

Page 1 of 2

A Form 4 filed with the SEC shows that David Roberson, a former Hewlett-Packard Company (NYSE:HPQ) executive who sits on the Board of Directors of International Game Technology (NYSE:IGT), bought 12,000 shares of International Game’s stock on November 30th at an average price of $13.94 per share. Roberson now owns a little over 18,000 shares, so this was a big purchase in percentage terms. We think that company insiders should tend to avoid buying the stock, as it reduces their diversification and leaves them more exposed to company-specific risks, unless the insider- benefitting from having more knowledge of the business and the industry than the average investor- is very confident that the stock will outperform. This is our explanation for why stocks bought by insiders beat the market on average (read more about studies on insider trading). Our database of insider purchases at International Game shows that another Board member bought stock in November at an average price of $13.25. Since consensus insider buying is a particularly bullish signal, we think it’s a good idea to take a closer look at the provider of electronic gaming systems.

The company’s fiscal year ended at the end of September. International Game Technology reported that revenue had risen 10% from the last fiscal year, with the largest increase in sales coming in the small Interactive segment. This increase in Interactive was partly due to an acquisition. Operating income dropped 16%, but that was entirely due to acquisition related costs and an increase in impairment and restructuring charges. With research and development expenses being 10% of sales after increasing about in line with revenue, it looks to us like the core business is doing moderately well. The fourth quarter of the fiscal year reflected a particularly impressive improvement from a year earlier, with revenue and earnings each increasing by over 15%.


At a market capitalization of $3.9 billion, International Game trades at 17 times trailing earnings. As we’ve noted its earnings have been brought lower in recent quarters by what should not be ongoing charges, so net income would be expected to improve going forward. Wall Street analysts agree with this logic, as consensus earnings for the current fiscal year are $1.21- a sizable increase, and implying a current-year P/E of 12. If the company turns out to be on track to reach that figure, we’d consider it as a value stock as the core business would need only modest growth to justify that valuation.

Page 1 of 2

Biotech Insider Alert - $5 Stock To Hit $40

$200 Million Dollar Healthcare Hedge Fund's #1 Best Idea Right Now

The best healthcare hedge fund out there right now is one of the largest shareholders in this biotech stock. The fund returned more than 20% in each of the last 2 years with a virtually fully hedged portfolio, and it's sending out a BUY signal on this biotech stock. Get your FREE REPORT today (retail value of $300)

This is a FREE report from Insider Monkey. Credit Card is NOT required.

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!